Federal Appeals Court Blocks Nationwide Mailing of Abortion Drug Mifepristone

On May 1, 2026, a three-judge panel of the Fifth U.S. Circuit Court of Appeals in New Orleans issued a ruling that temporarily reinstated a requirement that mifepristone — the first drug in the two-pill medication abortion regimen — be dispensed only in person at clinics [1]. The decision in Louisiana v. FDA blocks the mail-order and telehealth prescribing of the most common method of abortion in the United States, a method that had been growing rapidly since the Supreme Court overturned Roe v. Wade in 2022 [2].

The ruling has nationwide effect. It reverses an FDA regulation finalized under the Biden administration in 2023 that had eliminated the in-person dispensing requirement for mifepristone, allowing patients to receive the drug by mail after a telehealth consultation [3]. The decision sets up what legal observers on both sides expect to be another Supreme Court confrontation over abortion access — this time centered not on whether states can ban the procedure, but on whether the federal government can regulate how pills reach patients [4].

The Scale of What's at Stake

Medication abortion now accounts for roughly 65% of all abortions performed in the United States, up from just 6% when mifepristone was first approved by the FDA in 2000 [5]. Over 98% of medication abortions use a combination of mifepristone and misoprostol [5].

Source: Guttmacher Institute

Data as of May 1, 2026CSV

The growth of telehealth prescribing has been particularly steep. According to the Society of Family Planning's #WeCount research project, nearly 30% of all U.S. abortions in the first half of 2025 were provided through telehealth — up from fewer than 10% in 2022 [6]. In concrete terms, that means roughly 300,000 or more abortions per year now involve a patient consulting a provider remotely and receiving mifepristone by mail, rather than visiting a clinic in person.

Source: Society of Family Planning #WeCount

Data as of May 1, 2026CSV

In states with near-total abortion bans, telehealth has become a primary access point. An estimated 91,000 patients in ban states received telehealth abortions in 2025, including 9,350 in Louisiana itself, prescribed by physicians operating under shield laws in other states [5]. The Fifth Circuit's ruling threatens to cut off this pipeline entirely.

The Case: Louisiana v. FDA

Louisiana filed its lawsuit in October 2025, represented by Alliance Defending Freedom, the conservative legal organization that also spearheaded the Dobbs v. Jackson Women's Health Organization case that overturned Roe [7]. The state argued that the FDA's 2023 regulation allowing mail dispensing of mifepristone "create[s] an effective way for an out-of-state prescriber to place the drug in the hands of Louisianans in defiance of Louisiana law" [1].

The case moved quickly. After a district court denied Louisiana's request for a preliminary injunction in April 2026 and paused the litigation to allow the Trump administration's FDA to complete a new review of mifepristone regulations, Louisiana appealed [7]. On May 1, the Fifth Circuit granted Louisiana's emergency motion and reinstated the in-person dispensing requirement [1].

The panel's reasoning centered on a critique of the FDA's safety data practices. The judges wrote that the agency had "previously eliminated the requirement to report mifepristone's adverse events" and called it "unreasonable" to then rely on the resulting lack of reported data to justify expanded access [4]. The court also invoked Louisiana's sovereign interest, writing: "Every abortion facilitated by FDA's action cancels Louisiana's ban on medical abortions and undermines its policy that 'every unborn child is [a] human being … from the moment of conception'" [4][8].

The ruling did not directly invoke the Comstock Act of 1873, the Victorian-era anti-obscenity statute that prohibits mailing items used to produce an abortion [9]. However, separate cases in Texas and Missouri are pressing Comstock Act claims that could go further — potentially blocking the mailing of all abortion-related medications and supplies [9]. A Department of Justice Office of Legal Counsel opinion has concluded that the Comstock Act does not prohibit mailing abortion medications unless the sender intends for them to be used unlawfully, but opponents of that interpretation are seeking to overturn it through litigation [10].

The FDA's Authority Under Fire

The ruling raises a fundamental question about regulatory power: can a federal court override the FDA's determination of how a drug should be distributed?

The FDA approved mifepristone in 2000 under a Risk Evaluation and Mitigation Strategy (REMS), a framework that imposes specific conditions on how a drug is prescribed and dispensed [11]. Over time, the agency modified the REMS based on accumulating safety data: in 2016, it extended the approved gestational limit from seven to ten weeks, reduced the recommended dose, and approved a generic version [12]. In 2023, the agency eliminated the in-person dispensing requirement, allowing certified pharmacies to dispense mifepristone by mail [11].

The plaintiffs in the earlier Alliance for Hippocratic Medicine v. FDA case — a coalition of anti-abortion medical organizations — argued that the FDA's 2016 and 2023 expansions bypassed required safety protocols and that the agency had improperly used an "accelerated approval" pathway [12]. In June 2024, the Supreme Court unanimously rejected that challenge on standing grounds, finding that the plaintiff doctors had not demonstrated personal harm from the FDA's regulations [13]. The Court did not address the merits of their safety claims.

Louisiana's case avoids the standing problem by positioning a state — with its own abortion ban to enforce — as the plaintiff [7]. The Fifth Circuit accepted that a state has a cognizable interest in preventing federal regulations from undermining its own laws. Critics of the ruling argue this logic would allow any state to challenge any federal drug regulation that conflicts with state policy, opening the door to a flood of similar suits [5].

The Safety Record

Mifepristone has been used by more than 7.5 million patients in the United States since its approval in 2000 [11]. The FDA's postmarketing surveillance data through December 2024 records 36 deaths associated with the drug over that entire period [11]. That translates to a mortality rate of approximately 0.31 deaths per 100,000 medication abortions [14].

For context, the pregnancy-related mortality ratio in the United States is 17.6 deaths per 100,000 live births — roughly 14 times higher than the mortality rate associated with medication abortion [14]. Nonfatal serious adverse events, including hospitalization, blood transfusion, or serious infection, occur at rates between 0.01% and 0.7% [14]. The rate of major complications in large studies is approximately 0.31 per 100 procedures, with 94% of documented complications classified as minor [14].

A 2024 study published in Nature Medicine examined more than 6,000 patients who received medication abortion via telehealth across 20 states and Washington, D.C. The study found the medication was effective for 97.7% of patients, with 99.7% experiencing no serious adverse events — rates comparable to those documented in studies of in-person medication abortion [15]. The effectiveness was similar whether patients consulted providers by video (98.3%) or through asynchronous text-based platforms (97.4%) [15].

The Fifth Circuit panel, however, pointed to a gap in the evidence: because the FDA removed adverse event reporting requirements for mifepristone, the court argued, the safety data used to justify expanded access is inherently incomplete [4]. This argument echoes concerns raised by some pharmacovigilance researchers. A 2021 analysis published in the Health Services Research and Managerial Epidemiology journal compared adverse events reported to the FDA's official system with those identified through Planned Parenthood's internal records and Freedom of Information Act requests, finding discrepancies that the authors argued reflected underreporting [16].

Supporters of the ruling point to these data gaps as evidence that the FDA moved too quickly. The Family Research Council's Tony Perkins called the ruling "great news for the unborn" [4], while Students for Life President Kristan Hawkins said, "This is a win we've been waiting for" [4].

The Steelman Case for the Ruling

The strongest argument in favor of the ruling rests on a procedural claim: that the FDA's decision to relax mifepristone's REMS in 2016 and 2023 was not adequately supported by the agency's own safety framework. Specifically, ruling supporters argue that:

1. The FDA removed the requirement that prescribers report non-fatal adverse events in 2016, creating a surveillance blind spot. The agency then cited the low rate of reported adverse events as justification for further deregulation in 2023 — a circular logic that the Fifth Circuit called "unreasonable" [4].

2. The original approval of mifepristone in 2000 included an in-person dispensing requirement precisely because the drug carries risks — including heavy bleeding and incomplete abortion — that may require emergency medical intervention [12]. Removing that requirement transfers the burden of monitoring from clinicians to patients, some of whom may lack proximity to emergency care.

3. States with abortion bans have a legitimate sovereign interest in not having federal regulations used to circumvent their laws. The Fifth Circuit accepted this argument, reasoning that the FDA's mail-dispensing rule had the practical effect of nullifying Louisiana's abortion restrictions [1].

Legal scholars who support the ruling frame it as a question of administrative overreach. Jonathan Mitchell, the architect of Texas's SB 8 abortion law, has argued that the FDA lacks statutory authority to override state criminal law through drug-distribution regulations [7].

The International Comparison

The United States is an outlier among peer nations in restricting mail access to mifepristone.

In the United Kingdom, legislation has permanently embedded telemedicine as a routine component of abortion care. Patients can receive both mifepristone and misoprostol by mail after a remote consultation, with a gestational limit of 10 weeks [17]. A study of more than 50,000 patients found that 98.8% of telehealth abortions were completed safely, with no increase in complications compared to in-person care [17].

Canada has allowed community pharmacists to dispense mifepristone directly to patients since 2017, and between 2016 and 2019 removed several dispensing restrictions that had initially accompanied the drug's approval [18]. Telemedicine prescribing is permitted, and studies of Canadian pharmacists' experiences have documented successful implementation [18].

Australia has permitted pharmacist dispensing of mifepristone since 2012 and uses telemedicine extensively to reach patients in rural areas [19]. The country now has more certified mifepristone prescribers and pharmacist dispensers than facilities providing surgical abortion care [19].

France, where mifepristone was first developed and came into use in 1987, allows the drug to be prescribed up to seven weeks of gestation, though dispensing practices vary [20].

In each of these countries, expanded access has been accompanied by safety monitoring that has not identified increased risk compared to in-person dispensing.

The Collateral Damage: Miscarriage Care

Mifepristone is not only used for abortion. It is also prescribed off-label for the medical management of incomplete miscarriage — a condition affecting nearly one in five pregnancies [21]. The same mail-pharmacy supply chains disrupted by the Fifth Circuit's ruling serve patients experiencing pregnancy loss who are not seeking an abortion.

The American Medical Association has warned that "reducing access to mifepristone would harm patients" beyond the abortion context, a position echoed by the American College of Obstetricians and Gynecologists [21]. ACLU attorney Julia Kaye stated that the ruling "is going to affect patients' access to abortion and miscarriage care in every state in the nation" [2].

No comprehensive data exists on exactly how many miscarriage patients rely on mail-dispensed mifepristone specifically, a gap that reflects the same reporting limitations the Fifth Circuit critiqued in the abortion context. But with approximately 750,000 to 1 million clinically recognized miscarriages occurring annually in the United States, and with mifepristone-misoprostol being a standard treatment option, the population affected extends well beyond elective abortion [21].

The Access Gap

For patients in states where in-clinic mifepristone access is already restricted or banned, the loss of mail access compounds existing barriers. Research has documented that 75% of abortion patients are poor or low-income [22]. In Texas, after earlier restrictions, the average one-way distance to the nearest abortion provider increased from 17 to 70 miles [22]. Patients facing these distances must cover transportation costs, child care, lost wages, and sometimes overnight accommodations — barriers that fall hardest on those with the fewest resources.

ACLU attorney Julia Kaye summarized the distributional impact: "When telemedicine is restricted, rural communities, people with low incomes, people with disabilities, survivors of intimate partner violence and communities of color suffer the most" [2].

Thirty-four states currently have bans or restrictions on medication abortion, and 19 states already had in-person dispensing requirements that predated the FDA's 2023 rule change [22]. But for patients in the remaining states, and for those in ban states who had been accessing care through telehealth shield laws, the Fifth Circuit's ruling eliminates an access pathway that had been growing rapidly.

What Comes Next

The ruling is a temporary order — technically an injunction pending appeal — but its nationwide scope gives it immediate practical effect [1]. Legal observers expect an emergency appeal to the Supreme Court, which would face the question it sidestepped in 2024: whether the FDA's expansion of mifepristone access was lawful on the merits [13].

The conservative-majority Court has shown itself willing to engage with abortion-related cases since Dobbs, but its unanimous 2024 ruling dismissing the Alliance for Hippocratic Medicine challenge on standing grounds makes the outcome difficult to predict [13]. With a state as plaintiff, the standing issue that derailed the earlier case is likely resolved.

Meanwhile, the Trump administration's FDA is conducting its own review of mifepristone regulations, with an uncertain timeline and unpredictable conclusions [3]. The agency's position in Louisiana v. FDA has been ambiguous — it requested a pause in the litigation rather than mounting a vigorous defense of the 2023 rule [7].

The intersection of state abortion bans, federal drug regulation, and telehealth technology has produced a legal landscape with no clear precedent. The Fifth Circuit's ruling is the latest move in a conflict that shows no signs of resolution short of the Supreme Court.